What is CBUS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.12B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CBUS?

P/E (TTM) is n/a and 52-week range is $1.09 to $4.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CBUS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CBUS?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-9.76B, EPS (TTM) near $-1.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cibus Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 76.3M shares outstanding, ISIN US17166A1016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cibus Inc

$CBUS

Health Care · Biotechnology

IR Run Scenarios

$1.55

-2.52%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 118 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

Employees

118

Website

www.cibus.com/

IPO

2017-07-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)